logo

please indicate that you are over 18 to enter

are you 18 years or older?

List of Publications

Dr Karl Olov Fagerström

PhD

Journal Articles

  • Aubin, H. J., Bobak, A., Britton, J. R., Oncken, C., Billing, C. B., Gong, J., Williams, K. E., & Reeves, K. R. (2008). Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomised open-label trial. Thorax, 63(8), 717–724. https://doi.org/10.1136/THX.2007.090647
  • Fagerström, K. (1991). The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction, 86(9), 1119–1127. https://www.researchgate.net/publication/21222875_The_Fagerstrom_Test_for_Nicotine_Dependence_A_revision_of_the_Fagerstrom_Tolerance_Questionnaire
  • Fagerström, K. (2002). The epidemiology of smoking: Health consequences and benefits of cessation. Drugs, 62(Suppl 2), 1–9. https://www.researchgate.net/publication/11268469_The_epidemiology_of_smoking_Health_consequences_and_benefits_of_cessation
  • Fagerstrom, K. (2015). Varenicline can help smokers to stop smoking by gradual reduction. Evidence-Based Medicine, 20(4), 133. https://doi.org/10.1136/EBMED-2015-110199
  • Fagerström, K. (2022, April 12). Karl FAGERSTRÖM | PhD | 190+ Publications. Researchgate. https://www.researchgate.net/profile/Karl-Fagerstroem
  • Fagerstrom, K., Etter, J. F., & Unger, J. B. (2015). E-cigarettes: A disruptive technology that revolutionizes our field? Nicotine and Tobacco Research, 17(2), 125–126. https://doi.org/10.1093/NTR/NTU240
  • Fagerström, K. O., & Bridgman, K. (2014). Tobacco harm reduction: the need for new products that can compete with cigarettes. Addictive Behaviors, 39(3), 507–511. https://doi.org/10.1016/J.ADDBEH.2013.11.002
  • Fagerström, K. O., Hughes, J., & Callas, P. W. (2002). Long-term effects of the Eclipse cigarette substitute and the nicotine inhaler in smokers not interested in quitting. Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco, 4 Suppl 2(SUPPL. 2). https://doi.org/10.1080/1462220021000032771
  • Fagerström, K. O., & Hughes, J. R. (2002). Nicotine concentrations with concurrent use of cigarettes and nicotine replacement: a review. Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco, 4 Suppl 2(SUPPL. 2). https://doi.org/10.1080/1462220021000032753
  • Fagerström, K. O., Hughes, J. R., Rasmussen, T., & Callas, P. W. (2000). Randomised trial investigating effect of a novel nicotine delivery device (Eclipse) and a nicotine oral inhaler on smoking behaviour, nicotine and carbon monoxide exposure, and motivation to quit. Tobacco Control, 9(3), 327–333. https://doi.org/10.1136/TC.9.3.327
  • Fagerström, K. O., & Schildt, E. B. (2003). Should the European Union lift the ban on snus? Evidence from the Swedish experience. Addiction (Abingdon, England), 98(9), 1191–1195. https://doi.org/10.1046/J.1360-0443.2003.00442.X
  • Hasford, J., Fagerstrom, K. O., & Haustein, K. O. (2003). A naturalistic cohort study on effectiveness, safety and usage pattern of an over-the-counter nicotine patch. Cohort study on smoking cessation. European Journal of Clinical Pharmacology, 59(5–6), 443–447. https://doi.org/10.1007/S00228-003-0629-8
  • Jiménez-Ruiz, C. A., & Fagerström, K. O. (2013). Smoking cessation treatment for COPD smokers: The role of counselling. Monaldi Archives for Chest Disease - Pulmonary Series, 79(1), 33–37. https://doi.org/10.4081/MONALDI.2013.107
  • Jiménez-Ruiz, C. A., & Fagerström, K. O. (2013). Smoking cessation treatment for COPD smokers: The role of pharmacological interventions. Monaldi Archives for Chest Disease - Pulmonary Series, 79(1), 27–32. https://doi.org/10.4081/MONALDI.2013.106
  • Lunell, E., Fagerström, K., Hughes, J., & Pendrill, R. (2021). Pharmacokinetic comparison of a novel non-tobacco-based nicotine pouch (ZYN) with conventional, tobacco-based swedish snus and american moist snuff. Nicotine and Tobacco Research, 22(10), 1757–1763. https://doi.org/10.1093/NTR/NTAA068
  • Nutt, D. J., Phillips, L. D., Balfour, D., Curran, H. V., Dockrell, M., Foulds, J., Fagerstrom, K., Letlape, K., Milton, A., Polosa, R., Ramsey, J., & Sweanor, D. (2014). Estimating the harms of nicotine-containing products using the MCDA approach. European Addiction Research, 20(5), 218–225. https://doi.org/10.1159/000360220
  • Nutt, D. J., Phillips, L. D., Balfour, D., Curran, H. V., Dockrell, M., Foulds, J., Fagerstrom, K., Letlape, K., Polosa, R., Ramsey, J., & Sweanor, D. (2016). E-cigarettes are less harmful than smoking. The Lancet, 387(10024), 1160–1162. https://doi.org/10.1016/S0140-6736(15)00253-6
  • Plurphanswat, N., Hughes, J. R., Fagerström, K., & Rodu, B. (2020). Initial Information on a Novel Nicotine Product. American Journal on Addictions, 29(4), 279–286. https://doi.org/10.1111/AJAD.13020
  • Svicher, A., Cosci, F., Giannini, M., Pistelli, F., & Fagerström, K. (2018). Item Response Theory analysis of Fagerström Test for Cigarette Dependence. Addictive Behaviors, 77, 38–46. https://doi.org/10.1016/J.ADDBEH.2017.09.005
  • Sweeney, C. T., Fant, R. v., Fagerstrom, K. O., McGovern, J. F., & Henningfield, J. E. (2001). Combination nicotine replacement therapy for smoking cessation: Rationale, efficacy and tolerability. CNS Drugs, 15(6), 453–467. https://doi.org/10.2165/00023210-200115060-00004
  • Tonstad, S., Heggen, E., Giljam, H., Lagerbäck, P. Å., Tønnesen, P., Wikingsson, L. D., Lindblom, N., de Villiers, S., Svensson, T. H., & Fagerström, K. O. (2013). Niccine, a nicotine vaccine, for relapse prevention: A phase ii, randomized, placebo-controlled, multicenter clinical trial. Nicotine and Tobacco Research, 15(9), 1492–1501. https://doi.org/10.1093/NTR/NTT003

reports

videos